Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorption

Hemoglobin

Volumn 34, Issue 3, 2010, Pages 251-264

  Kontoghiorghes, George J ^a   Spyrou, Aspasia ^a   Kolnagou, Annita ^a  

^a Postgraduate Research Institute of Science Technology Environment and Medicine Limassol   (Cyprus)

Author keywords

Chelation therapy; Deferasirox (DFRA); Deferiprone (L1); Deferoxamine (DFO); Hereditary hemochromatosis; Thalassemia intermedia

Indexed keywords

8 QUINOLINOL; CHELATING AGENT; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN; FERROPORTIN; HEPCIDIN; HYDROXYUREA; IRON; IRON CHELATING AGENT; LACTOFERRIN; MALTOL; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 1; TETRACYCLINE; TRANSFERRIN;

BETA THALASSEMIA; CHELATION THERAPY; CONFERENCE PAPER; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GENE MUTATION; HEART INJURY; HEMOCHROMATOSIS; HEREDITY; HUMAN; INCIDENCE; IRON ABSORPTION; IRON DEFICIENCY; IRON METABOLISM; IRON OVERLOAD; LIVER INJURY; NONHUMAN; PHLEBOTOMY; PROTEIN EXPRESSION;

CHELATION THERAPY; HEMOCHROMATOSIS; HUMANS; IRON; IRON CHELATING AGENTS; THALASSEMIA;

EID: 77953279403     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630269.2010.486335     Document Type: Conference Paper

References (28)

1. Feder J N, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996;13(4):339-408.
2. World Health Organization. Community control of hereditary anaemias. Bull WHO. 1983;61(1):63-80.
3. Weatherall DJ, Clegg JB. The Thalassaemia Syndromes, 3rd ed. Oxford: Blackwell Scientific Publications, 1981.
4. Barton JC, Edwards CQ. Hemochromatosis. Genetics, pathophysiology, diagnosis and treatment. Cambridge: Cambridge University Press, 2000.
5. Kontoghiorghes GJ, Kolnagou A. Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease. The role of natural and synthetic chelators. Curr Med Chem. 2005;12(23):2695-2709.
6. Green R, Charlton R, Seftel H, et al. Body iron excretion in man: a collaborative study. Am J Med. 1968;45(3):336-353.
7. Kontoghiorghes GJ. Chelators affecting iron absorption in mice. Arzneimittelforschung. 1990;40(12):1332-1335.
8. Kontoghiorghes GJ, Eracleous E, Economides Ch, Kolnagou A. Advances in iron overload therapies. Prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NAll and their combinations. Curr Med Chem. 2005;12(23):2663-2681.
9. Pantopoulos K. Function of the hemochromatosis protein HFE: lessons from animal models. World J Gastroenterol. 2008;14(45):6893-6901.
10. Byrnes V, Barrett S, Ryan E, et al. Increased duodenal DMT1 expression and unchanged HFE mRNA levels in HFE-associated hereditary hemochromatosis and iron deficiency. Blood Cells Mol Dis. 2002;29(3):251-260.
11. Kontoghiorghes GJ. Structure/red blood cell permeability activity of iron (III) chelator complexes. Inorg Chim Acta. 1988;151:101-106.
12. Djaldetti M, Fishman P, Notti I, Bessler H. The effect of tetracycline administration on iron absorption in mice. Biomedicine. 1981;35(5):150-152. (Pubitemid 12174174)
13. Kontoghiorghes GJ, May A. Uptake and intracellular distribution of iron from transferrin and chelators in erythroid cells. Biol Met. 1990;3(3-4):183-187.
14. Forsbeck K, Nilsson K, Kontoghiorghes GJ.Variation in iron accumulation, transferrin membrane binding and DNA synthesis in the K-562 and U-937 cell lines induced by chelators and their iron complexes. Eur J Haematol. 1987;39(4):318-325.
15. Italia KY, Jijina FJ, Merchant R, et al. Response to hydroxyurea in β-thalassemia major and intermedia: experience in western India. Clin Chim Acta. 2009;407(1-2):10-15.
16. Patrinos GP, Grosveld FG. Pharmacogenomics and therapeutics of hemoglobinopathies. Hemoglobin. 2008;32(1-2):229-236.
17. Pippard MJ, Callender ST, Warner GT, Weatherall DJ. Iron absorption and loading in β-thalassaemia intermedia. Lancet. 1979;2(8147):819-821.
18. Papanikolaou G, Samuels ME, Ludwig EH, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet. 2004;36(1):77-82.
19. Camaschella C, Roetto A, Calì A, et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet. 2000;25(1):14-15.
20. Njajou OT, Vaessen N, Joosse M, et al. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. Nat Genet. 2001;28(3):213-214.
21. Kontoghiorghes GJ. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients. Hemoglobin. 2009; 33(5):332-338.
22. Yamamoto RS, Williams GM, Frangel HH, Weisburger JH. 8-Hydroxyquinoline: chronic toxicity and inhibitory effect on the carcinogenicity of N-2-fluorenylacetamide. Toxicol Appl Pharmacol. 1971;19(4):687-698.
23. Kontoghiorghes GJ. Transparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwide. Hemoglobin. 2008;32(6):608-615.
24. Nielsen P, Fischer R, Buggisch P, Janka-Schaub G. Effective treatment of hereditary haemochromatosis with desferrioxamine in selected cases. Br J Haematol. 2003;123(5):952-953.
25. Olivieri NF, Koren G, Matsui D, et al. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood. 1992;79(10):2741-2748.
26. Pootrakul P, Sirankapracha P, Sankote J, et al. Clinical trial of deferiprone iron chelation therapy in β-thalassaemia/Haemoglobin E patients in Thailand. Br J Haematol. 2003;122(2):305-310.
27. Fabio G, Minonzio F, Delbini P, Bianchi A, Cappellini MD. Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH). Blood. 2007;109(1):362-364.
28. Kontoghiorghes GJ, Kolnagou A, Peng CT, Shah SV, Aessopos A. Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases. Expert Opin Drug Saf. 2010; 9(2):201-206.